1. Aabo K, Pedersen AG, Hald I, Dombernowsky P (1982) High-dose medroxyprogesterone acetate (MPA) in advanced chemotherapy-resistant ovarian carcinoma: a phase II study. Cancer Treat Rep 66:407?408
2. Alberts DS, Salmon SE, Chen HSG, Surwit EA, Soehnlen B, Young L, Moon TE (1980) In-vitro clonogenic assay for predicting response of ovarian cancer to chemotherapy Lancet 2:340?342
3. Altman SJ, Metter GE, Nealon TF, Weiss AJ, Ramirez G, Madden RE, Fletcher WS, Strawitz JG, Multhauf PM (1978) Yoshi 864 [1-propanol 3-3-iminodi, dimethonesulfonate (ester), hydrochloride]: a phase II study in solid tumors. Cancer Treat Rep 62:389?395
4. Ames MM, Kovach JS (1982) Parenteral formulation of hexamethylmelamine potentially suitable for use in man. Cancer Treat Rep 66:1579?1581
5. Arsenau JC, Bundy B, Homesley H, Beecham J (1983) Phase II study of Baker's antifol (triazinate, TZT, NSC 139, 105) in advanced carcinoma of the ovary. Invest New Drugs 1:185?188